Audit Opinion - The audit report states that the financial statements of Shenzhen Micu Biotechnology Co., Ltd. (referred to as "Micu Bio") fairly reflect its financial position as of December 31, 2024, in accordance with the accounting standards issued by the Ministry of Finance of the People's Republic of China [1][2]. Key Audit Matters - Capitalization of development expenditures amounted to RMB 125,271,997.57 for the year 2024, with a cumulative balance of RMB 152,216,111.48 as of December 31, 2024. The audit identified this as a key audit matter due to significant management judgment involved in determining whether the expenditures meet the capitalization criteria [1][2][3]. - The audit procedures included evaluating internal controls related to the capitalization of development expenditures, obtaining relevant approvals and feasibility reports, and assessing the technical feasibility of the projects [1][2]. Company Overview - Shenzhen Micu Biotechnology Co., Ltd. was established on March 29, 2018, and is primarily engaged in drug technology development, new drug research, and production of pharmaceuticals and health food [5][6]. - The company operates under the accounting standards set by the Ministry of Finance and adheres to the disclosure requirements of the China Securities Regulatory Commission [5][6]. Financial Reporting Basis - The financial statements are prepared on a going concern basis, indicating that the company has the ability to continue its operations for at least 12 months from the reporting date without significant uncertainties [5][6]. Accounting Policies - The company has specific accounting policies for recognizing and measuring bad debt provisions, inventory valuation, and the capitalization of research and development costs, which are tailored to its operational characteristics [6][7]. - The financial statements comply with the requirements of the Ministry of Finance and reflect the company's financial condition and results of operations accurately [6][7]. Financial Instruments - The company classifies its financial assets and liabilities based on their management business model and cash flow characteristics, with initial recognition at fair value [10][11]. - Financial assets are subsequently measured at either amortized cost or fair value, depending on their classification [10][11].

Core Viewpoint - The legal opinion letter issued by Shanghai Tongli Law Firm confirms that Shenzhen Micron Biotech Co., Ltd. has complied with relevant laws and regulations for its upcoming issuance of A-shares to specific investors, pending approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [2][3][24]. Summary by Sections Legal Framework and Compliance - The legal opinion is based on the Securities Law, Company Law, and other relevant regulations, ensuring that the issuance process adheres to established legal standards [2][3]. - The law firm has verified that all documents provided by the issuer are complete and accurate, and the issuer has the necessary authority to conduct the issuance [2][3]. Issuance Details - The company plans to issue no more than 58,125,305 shares, which will not exceed 30% of the total share capital before the issuance [8][20]. - The issuance will be conducted through a competitive bidding process, with the issuance price set at no less than 80% of the average trading price over the previous 20 trading days [9][21]. Use of Proceeds - The total amount to be raised from the issuance is capped at 950 million yuan, which will be allocated to innovative drug research and development projects, including the establishment of a new manufacturing base [11][20]. - Prior to the funds being raised, the company may use its own or self-raised funds to initiate project implementation, with a plan to replace these with the raised funds once available [11][13]. Corporate Governance - The board of directors and shareholders have approved all necessary resolutions related to the issuance, ensuring compliance with corporate governance standards [6][14]. - The company has established a clear plan for shareholder returns over the next three years, aligning with the interests of its investors [6][12]. Independence and Control - The company operates independently from its major shareholders and has a complete production and sales system, ensuring no significant adverse impact from related party transactions [25][26]. - The major shareholders and actual controllers have been verified to not have any significant legal issues that could affect the company's operations or investor interests [19][26].

Core Viewpoint - Shenzhen Chipscreen Co., Ltd. is preparing for a specific issuance of A-shares in 2024, with the underwriting by Guotou Securities, emphasizing its commitment to compliance and due diligence in the process [1][2]. Company Overview - Shenzhen Chipscreen Co., Ltd. was established on March 21, 2001, with a registered capital of 408.54 million yuan and is listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board under the stock code 688321 [5]. - The company focuses on providing affordable, clinically needed innovative drugs, with a complete capability from drug discovery to commercialization [3]. Main Business - The company has products in commercialization, with core pipelines undergoing global registration clinical trials. Its main products include: - **Westabamine**: Approved for multiple cancers in China, Japan, and Taiwan, recognized as a first-line treatment for certain lymphomas [4][7]. - **Sigraglitazone**: Approved for Type 2 diabetes and included in medical insurance, with plans to promote its unique advantages in metabolic disease management [4][17]. Research and Development - The company has a robust R&D team of 272 personnel, with a high percentage holding advanced degrees, focusing on innovative drug discovery [5]. - As of March 31, 2025, the company holds 191 authorized invention patents, ensuring a comprehensive global patent strategy to protect its products [6]. Financial Data - As of March 31, 2025, the total assets of the company amounted to 3.31 billion yuan, with total liabilities of 1.75 billion yuan and equity attributable to shareholders of 1.56 billion yuan [23]. - For the first quarter of 2025, the company reported an operating income of 162.26 million yuan, with a net profit attributable to shareholders of -19.15 million yuan [23]. Clinical Trials and Product Pipeline - The company is advancing several clinical trials, including: - **Westabamine**: Involved in multiple Phase III trials for various cancers, showing promising results in combination therapies [12][14]. - **Sigraglitazone**: Demonstrated significant efficacy in controlling blood sugar levels and improving lipid metabolism in Type 2 diabetes patients [18][19]. - **Xiaoroni**: A multi-target kinase inhibitor currently in clinical trials for pancreatic and ovarian cancers [20][21]. Market Position and Strategy - The company aims to transform "cold tumors" into "hot tumors" to enhance immunotherapy responses, positioning itself strategically in the oncology market [15]. - Collaborations with international partners for global development and commercialization of its products are underway, marking a significant step in expanding its market reach [16].

Core Viewpoint - Shenzhen Chipscreen Biosciences Co., Ltd. is preparing for a specific issuance of A-shares in 2024, with Guotou Securities acting as the sponsor, ensuring compliance with relevant laws and regulations [1][2]. Group 1: Issuance Details - Guotou Securities has been appointed as the sponsor for the issuance of A-shares for Shenzhen Chipscreen in 2024, with representatives Hu Jiabin and Song Qian responsible for the due diligence and ongoing supervision [2][3]. - The issuance will involve a maximum of 58,125,305 shares, not exceeding 30% of the total share capital prior to the issuance [23][24]. Group 2: Company Overview - Shenzhen Chipscreen was established on March 21, 2001, with a registered capital of 408.54 million yuan and is listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board [5]. - The company focuses on drug technology development, new drug research, and related services, with a commitment to innovation in the biopharmaceutical sector [5]. Group 3: Financial Performance - As of March 31, 2025, the total assets of the company amounted to 331,170.31 million yuan, with total liabilities of 174,984.07 million yuan [8]. - The company reported a total revenue of 16,226.37 million yuan for the first quarter of 2025, with a net loss attributable to shareholders of 1,915.47 million yuan [8]. Group 4: Shareholder Structure - As of March 31, 2025, the top ten shareholders collectively hold 41.48% of the company's shares, with significant stakes held by various investment partnerships [5][11]. - The actual controller, Xianping Lu, holds 5.45% of the shares directly and controls a total of 22.00% through various partnerships [11][12]. Group 5: Future Plans and Use of Proceeds - The funds raised from the issuance will be allocated to innovative drug research and development projects, including the establishment of a new drug manufacturing base [23][24]. - The company has not distributed profits from 2022 to 2024, focusing on reinvestment for growth and development [6].

Core Viewpoint - Shenzhen Micu Biotechnology Co., Ltd. has received acceptance from the Shanghai Stock Exchange for its application to issue A-shares to specific investors, marking a significant step in its capital raising efforts [1][2]. Group 1: Company Announcement - The company announced that it received a notification from the Shanghai Stock Exchange on August 22, 2025, regarding the acceptance of its securities issuance application [1]. - The application documents were verified to be complete and in compliance with legal requirements, leading to the decision for acceptance and review by the exchange [1]. - The issuance of A-shares is subject to further review by the Shanghai Stock Exchange and approval from the China Securities Regulatory Commission, indicating that the process is not yet finalized [1]. Group 2: Regulatory Process - The company will keep investors informed about the progress of the application and any developments related to the review and approval process [1].

深圳微芯生物科技股份有限公司 2024 年度向特定对象发行 A 股股票募集说明书 股票简称：微芯生物 股票代码：688321 深圳微芯生物科技股份有限公司 2024 年度向特定对象发行 A 股股票 募集说明书 （申报稿） 保荐机构（主承销商） （深圳市福田区福田街道福华一路119号安信金融大厦） 二〇二五年八月 深圳微芯生物科技股份有限公司 2024 年度向特定对象发行 A 股股票募集说明书 声 明 本公司及全体董事、监事、高级管理人员承诺本募集说明书内容真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏，按照诚信原则履行承诺，并承 担相应的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证券监督管理委员会、上海证券交易所对本次发行所作的任何决定或意 见，均不表明其对申请文件及所披露信息的真实性、准确性、完整性作出保证， 也不表明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断 或保证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价 ...

深圳微芯生物科技股份有限公司 关于 2024 年度向特定对象发行 A 股股票申请获得 证券代码：688321 证券简称：微芯生物 公告编号：2025-050 上海证券交易所受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳微芯生物科技股份有限公司（以下简称"公司"）于2025年8月22日收 到上海证券交易所（以下简称"上交所"）出具的《关于受理深圳微芯生物科技 股份有限公司科创板上市公司发行证券申请的通知》（上证科审（再融资）〔2025〕 101号），上交所依据相关规定对公司报送的科创板上市公司发行证券的募集说 明书及相关申请文件进行了核对，认为该项申请文件齐备，符合法定形式，决定 予以受理并依法进行审核。 公司本次向特定对象发行A股股票事项尚需通过上交所审核，并获得中国证 券监督管理委员会（以下简称"中国证监会"）作出同意注册的决定后方可实施， 最终能否通过上交所审核，并获得中国证监会同意注册的决定及其时间尚存在不 确定性。公司将根据该事项的进展情况及时履行信息披露义务，敬请广大投资者 注意投资风险。 特此 ...

深圳微芯生物科技股份有限公司 2024 年度财务审计报告 6-1-1 审计报告 毕马威华振审字第 2512603 号 深圳微芯生物科技股份有限公司全体股东： 一、审计意见 我们审计了后附的深圳微芯生物科技股份有限公司 (以下简称"微芯生物") 财务报表，包 括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并 及母公司现金流量表、合并及母公司股东权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照中华人民共和国财政部颁布的企业会计准 则 (以下简称"企业会计准则") 的规定编制，公允反映了微芯生物 2024 年 12 月 31 日的合并 及母公司财务状况以及 2024 年度的合并及母公司经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则 (以下简称"审计准则") 的规定执行了审计工作。审计 报告的"注册会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按 照中国注册会计师职业道德守则，我们独立于微芯生物，并履行了职业道德方面的其他责任。 我们相信，我们获取的审计证据是充分、适当的，为发表审计意 ...

深圳微芯生物科技股份有限公司 上市保荐书 国投证券股份有限公司 关于深圳微芯生物科技股份有限公司 2024 年度向特定对象发行 A 股股票 之 上市保荐书 保荐机构（主承销商） 二〇二五年八月 3-2-1 深圳微芯生物科技股份有限公司 上市保荐书 上海证券交易所： 国投证券股份有限公司（以下简称"国投证券"或"保荐机构"）接受深圳 微芯生物科技股份有限公司（以下简称"微芯生物"、"发行人"、"上市公司" 或"公司"）的委托，担任其 2024 年度向特定对象发行 A 股股票的保荐人。 保荐机构及保荐代表人根据《中华人民共和国公司法》《中华人民共和国证 券法》《证券发行上市保荐业务管理办法》《上市公司证券发行注册管理办法》 《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司证券发行与 承销业务实施细则》等有关法律、行政法规和中国证券监督管理委员会、上海证 券交易所的规定，诚实守信，勤勉尽责，严格按照依法制定的业务规则和行业自 律规范出具上市保荐书，并保证所出具文件真实、准确、完整。 本上市保荐书如无特别说明，相关用语与《深圳微芯生物科技股份有限公司 2024 年度向特定对象发行 A 股股票募集说明书》中 ...

上海市通力律师事务所 关于 深圳微芯生物科技股份有限公司 2024 年度向特定对象发行股票 之 法律意见书 二〇二五年八月 | （引 | 言） | 2 | | --- | --- | --- | | （正 | 文） | 3 | | 一. | 本次发行的批准和授权 | 10 | | 二. | 发行人本次发行的主体资格 | 20 | | 三. | 本次发行的实质条件 | 21 | | 四. | 发行人的设立 | 27 | | 五. | 发行人的独立性 | 28 | | 六. | 发行人的主要股东与实际控制人 | 30 | | 七. | 发行人的股本及演变 | 32 | | 八. | 发行人的业务 | 38 | | 九. | 关联交易及同业竞争 | 39 | | 十. | 发行人的主要资产 | 45 | | 十一. | 发行人的重大债权、债务关系 | 52 | | 十二. | 发行人的重大资产变化及收购兼并 | 53 | | 十三. | 发行人章程的制定与修改 | 54 | | 十四. | 发行人股东大会、董事会、监事会议事规则及规范运作 | 54 | | 十五. | 发行人董事、监事、高级管理人员和核心技术人员变 ...